The Latin America, Middle East and Africa Non Hodgkin Lymphoma Therapeutics Market would witness market growth of 11.3% CAGR during the forecast period (2023-2030).
Drugs like ibrutinib and idelalisib are increasingly used in patients with relapsed or refractory NHL, providing alternative treatment options beyond traditional chemotherapy. In cases of relapse or refractory disease, high-dose chemotherapy followed by autologous stem cell transplantation may be considered salvage therapy. This approach aims to eradicate cancer cells and restore normal blood cell production. Along with active cancer-directed therapies, NHL therapeutics include supportive care measures to manage treatment-related side effects. This may include medications to alleviate nausea, prevent infections, and manage hematologic toxicities.
In advanced stages or cases where curative treatment is not feasible, NHL therapeutics, including palliative chemotherapy and symptom-focused interventions, aim to enhance quality of life by alleviating symptoms and improving overall well-being. Genomic and molecular profiling advances have led to the identification of specific genetic alterations and biomarkers associated with NHL. This information is used to guide treatment decisions, allowing for a more targeted and personalized approach. Participation in clinical trials involving novel agents, innovative immunotherapies, and experimental treatment approaches offers patients access to cutting-edge therapies and enhances NHL treatment paradigms.
Advances in understanding the genetic and molecular characteristics of NHL allow for developing targeted therapies in South Africa. Clinical trials investigate drugs targeting pathways or mutations involved in NHL progression in South Africa. Clinical trials involve discovering and validating biomarkers that can help predict treatment response and guide personalized treatment plans for patients with NHL in South Africa. Innovations in healthcare delivery, including telemedicine and remote monitoring, are explored in clinical trials in South Africa. These approaches can improve access to care, especially for patients in remote or underserved areas in South Africa. Therefore, due to these aspects, the market will expand across the LAMEA region in upcoming years.
The Brazil market dominated the LAMEA Non Hodgkin Lymphoma Therapeutics Market by Country in 2022, and would continue to be a dominant market till 2030; thereby, achieving a market value of $301.6 Million by 2030. Argentina market is exhibiting a CAGR of 11.9% during (2023 - 2030). Additionally, The UAE market would experience a CAGR of 11% during (2023 - 2030).
Free Valuable Insights: The Worldwide Non Hodgkin Lymphoma Therapeutics Market is Projected to reach USD 16.8 Billion by 2030, at a CAGR of 8.4%
Based on Cell Type, the market is segmented into B-Cell Lymphoma and T-Cell Lymphoma. Based on Therapy Type, the market is segmented into Radiation Therapy, Chemotherapy, Targeted Therapy, and Others. Based on countries, the market is segmented into Brazil, Argentina, UAE, Saudi Arabia, South Africa, Nigeria, and Rest of LAMEA.
List of Key Companies Profiled
- Pfizer Inc.
- F.Hoffmann-La Roche Ltd
- Sanofi S.A.
- AbbVie, Inc.
- Novartis AG
- GlaxoSmithKline PLC
- Johnson & Johnson (Johnson & Johnson Services, Inc.)
- Takeda Pharmaceutical Company Limited
- Bayer AG
- Bristol-Myers Squibb Company
LAMEA Non Hodgkin Lymphoma Therapeutics Market Report Segmentation
By Cell Type
- B-Cell Lymphoma
- T-Cell Lymphoma
By Therapy Type
- Radiation Therapy
- Chemotherapy
- Targeted Therapy
- Others
By Country
- Brazil
- Argentina
- UAE
- Saudi Arabia
- South Africa
- Nigeria
- Rest of LAMEA
Chapter 1. Market Scope & Methodology
1.1 Market Definition
1.2 Objectives
1.3 Market Scope
1.4 Segmentation
1.4.1 LAMEA Non Hodgkin Lymphoma Therapeutics Market, by Cell Type
1.4.2 LAMEA Non Hodgkin Lymphoma Therapeutics Market, by Therapy Type
1.4.3 LAMEA Non Hodgkin Lymphoma Therapeutics Market, by Country
1.5 Methodology for the research
Chapter 2. Market at a Glance
2.1 Key Highlights
Chapter 3. Market Overview
3.1 Introduction
3.1.1 Overview
3.1.1.1 Market Composition and Scenario
3.2 Key Factors Impacting the Market
3.2.1 Market Drivers
3.2.2 Market Restraints
3.3 Porter Five Forces Analysis
Chapter 4. Strategies Deployed in Non Hodgkin Lymphoma Therapeutics Market.
Chapter 5. LAMEA Non Hodgkin Lymphoma Therapeutics Market by Cell Type
5.1 LAMEA B-Cell Lymphoma Market by Country
5.2 LAMEA T-Cell Lymphoma Market by Country
Chapter 6. LAMEA Non Hodgkin Lymphoma Therapeutics Market by Therapy Type
6.1 LAMEA Radiation Therapy Market by Country
6.2 LAMEA Chemotherapy Market by Country
6.3 LAMEA Targeted Therapy Market by Country
6.4 LAMEA Others Market by Country
Chapter 7. LAMEA Non Hodgkin Lymphoma Therapeutics Market by Country
7.1 Brazil Non Hodgkin Lymphoma Therapeutics Market
7.1.1 Brazil Non Hodgkin Lymphoma Therapeutics Market by Cell Type
7.1.2 Brazil Non Hodgkin Lymphoma Therapeutics Market by Therapy Type
7.2 Argentina Non Hodgkin Lymphoma Therapeutics Market
7.2.1 Argentina Non Hodgkin Lymphoma Therapeutics Market by Cell Type
7.2.2 Argentina Non Hodgkin Lymphoma Therapeutics Market by Therapy Type
7.3 UAE Non Hodgkin Lymphoma Therapeutics Market
7.3.1 UAE Non Hodgkin Lymphoma Therapeutics Market by Cell Type
7.3.2 UAE Non Hodgkin Lymphoma Therapeutics Market by Therapy Type
7.4 Saudi Arabia Non Hodgkin Lymphoma Therapeutics Market
7.4.1 Saudi Arabia Non Hodgkin Lymphoma Therapeutics Market by Cell Type
7.4.2 Saudi Arabia Non Hodgkin Lymphoma Therapeutics Market by Therapy Type
7.5 South Africa Non Hodgkin Lymphoma Therapeutics Market
7.5.1 South Africa Non Hodgkin Lymphoma Therapeutics Market by Cell Type
7.5.2 South Africa Non Hodgkin Lymphoma Therapeutics Market by Therapy Type
7.6 Nigeria Non Hodgkin Lymphoma Therapeutics Market
7.6.1 Nigeria Non Hodgkin Lymphoma Therapeutics Market by Cell Type
7.6.2 Nigeria Non Hodgkin Lymphoma Therapeutics Market by Therapy Type
7.7 Rest of LAMEA Non Hodgkin Lymphoma Therapeutics Market
7.7.1 Rest of LAMEA Non Hodgkin Lymphoma Therapeutics Market by Cell Type
7.7.2 Rest of LAMEA Non Hodgkin Lymphoma Therapeutics Market by Therapy Type
Chapter 8. Company Profiles
8.1 Pfizer, Inc.
8.1.1 Company Overview
8.1.2 Financial Analysis
8.1.3 Regional & Segmental Analysis
8.1.4 Research & Development Expense
8.1.5 Recent strategies and developments:
8.1.5.1 Partnerships, Collaborations, and Agreements:
8.1.5.2 Product Launches and Product Expansions:
8.1.5.3 Acquisition and Mergers:
8.1.6 SWOT Analysis
8.2 F. Hoffmann-La Roche Ltd.
8.2.1 Company Overview
8.2.2 Financial Analysis
8.2.3 Segmental and Regional Analysis
8.2.4 Research & Development Expense
8.2.5 SWOT Analysis
8.3 Sanofi S.A.
8.3.1 Company Overview
8.3.2 Financial Analysis
8.3.3 Segmental and Regional Analysis
8.3.4 Research & Development Expense
8.3.5 Recent strategies and developments:
8.3.5.1 Partnerships, Collaborations, and Agreements:
8.3.6 SWOT Analysis
8.4 AbbVie, Inc.
8.4.1 Company Overview
8.4.2 Financial Analysis
8.4.3 Regional Analysis
8.4.4 Research & Development Expense
8.4.5 Recent strategies and developments:
8.4.5.1 Acquisition and Mergers:
8.4.6 SWOT Analysis
8.5 Novartis AG
8.5.1 Company Overview
8.5.2 Financial Analysis
8.5.3 Segmental and Regional Analysis
8.5.4 Research & Development Expense
8.5.5 Recent strategies and developments:
8.5.5.1 Acquisition and Mergers:
8.5.6 SWOT Analysis
8.6 GlaxoSmithKline PLC
8.6.1 Company Overview
8.6.2 Financial Analysis
8.6.3 Regional Analysis
8.6.4 Research & Development Expense
8.6.5 Recent strategies and developments:
8.6.5.1 Partnerships, Collaborations, and Agreements:
8.6.6 SWOT Analysis
8.7 Johnson & Johnson (Johnson & Johnson Services, Inc.)
8.7.1 Company Overview
8.7.2 Financial Analysis
8.7.3 Segmental &Regional Analysis
8.7.4 SWOT Analysis
8.8 Takeda Pharmaceutical Company Limited
8.8.1 Company Overview
8.8.2 Financial Analysis
8.8.3 Regional Analysis
8.8.4 Research & Development Expense
8.8.5 SWOT Analysis
8.9 Bayer AG
8.9.1 Company Overview
8.9.2 Financial Analysis
8.9.3 Segmental and Regional Analysis
8.9.4 Research & Development Expense
8.9.5 SWOT Analysis
8.10. Bristol-Myers Squibb Company
8.10.1 Company Overview
8.10.2 Financial Analysis
8.10.3 Regional Analysis
8.10.4 Research & Development Expenses
8.10.5 SWOT Analysis
TABLE 1 LAMEA Non Hodgkin Lymphoma Therapeutics Market, 2019 - 2022, USD Million
TABLE 2 LAMEA Non Hodgkin Lymphoma Therapeutics Market, 2023 - 2030, USD Million
TABLE 3 LAMEA Non Hodgkin Lymphoma Therapeutics Market by Cell Type, 2019 - 2022, USD Million
TABLE 4 LAMEA Non Hodgkin Lymphoma Therapeutics Market by Cell Type, 2023 - 2030, USD Million
TABLE 5 LAMEA B-Cell Lymphoma Market by Country, 2019 - 2022, USD Million
TABLE 6 LAMEA B-Cell Lymphoma Market by Country, 2023 - 2030, USD Million
TABLE 7 LAMEA T-Cell Lymphoma Market by Country, 2019 - 2022, USD Million
TABLE 8 LAMEA T-Cell Lymphoma Market by Country, 2023 - 2030, USD Million
TABLE 9 LAMEA Non Hodgkin Lymphoma Therapeutics Market by Therapy Type, 2019 - 2022, USD Million
TABLE 10 LAMEA Non Hodgkin Lymphoma Therapeutics Market by Therapy Type, 2023 - 2030, USD Million
TABLE 11 LAMEA Radiation Therapy Market by Country, 2019 - 2022, USD Million
TABLE 12 LAMEA Radiation Therapy Market by Country, 2023 - 2030, USD Million
TABLE 13 LAMEA Chemotherapy Market by Country, 2019 - 2022, USD Million
TABLE 14 LAMEA Chemotherapy Market by Country, 2023 - 2030, USD Million
TABLE 15 LAMEA Targeted Therapy Market by Country, 2019 - 2022, USD Million
TABLE 16 LAMEA Targeted Therapy Market by Country, 2023 - 2030, USD Million
TABLE 17 LAMEA Others Market by Country, 2019 - 2022, USD Million
TABLE 18 LAMEA Others Market by Country, 2023 - 2030, USD Million
TABLE 19 LAMEA Non Hodgkin Lymphoma Therapeutics Market by Country, 2019 - 2022, USD Million
TABLE 20 LAMEA Non Hodgkin Lymphoma Therapeutics Market by Country, 2023 - 2030, USD Million
TABLE 21 Brazil Non Hodgkin Lymphoma Therapeutics Market, 2019 - 2022, USD Million
TABLE 22 Brazil Non Hodgkin Lymphoma Therapeutics Market, 2023 - 2030, USD Million
TABLE 23 Brazil Non Hodgkin Lymphoma Therapeutics Market by Cell Type, 2019 - 2022, USD Million
TABLE 24 Brazil Non Hodgkin Lymphoma Therapeutics Market by Cell Type, 2023 - 2030, USD Million
TABLE 25 Brazil Non Hodgkin Lymphoma Therapeutics Market by Therapy Type, 2019 - 2022, USD Million
TABLE 26 Brazil Non Hodgkin Lymphoma Therapeutics Market by Therapy Type, 2023 - 2030, USD Million
TABLE 27 Argentina Non Hodgkin Lymphoma Therapeutics Market, 2019 - 2022, USD Million
TABLE 28 Argentina Non Hodgkin Lymphoma Therapeutics Market, 2023 - 2030, USD Million
TABLE 29 Argentina Non Hodgkin Lymphoma Therapeutics Market by Cell Type, 2019 - 2022, USD Million
TABLE 30 Argentina Non Hodgkin Lymphoma Therapeutics Market by Cell Type, 2023 - 2030, USD Million
TABLE 31 Argentina Non Hodgkin Lymphoma Therapeutics Market by Therapy Type, 2019 - 2022, USD Million
TABLE 32 Argentina Non Hodgkin Lymphoma Therapeutics Market by Therapy Type, 2023 - 2030, USD Million
TABLE 33 UAE Non Hodgkin Lymphoma Therapeutics Market, 2019 - 2022, USD Million
TABLE 34 UAE Non Hodgkin Lymphoma Therapeutics Market, 2023 - 2030, USD Million
TABLE 35 UAE Non Hodgkin Lymphoma Therapeutics Market by Cell Type, 2019 - 2022, USD Million
TABLE 36 UAE Non Hodgkin Lymphoma Therapeutics Market by Cell Type, 2023 - 2030, USD Million
TABLE 37 UAE Non Hodgkin Lymphoma Therapeutics Market by Therapy Type, 2019 - 2022, USD Million
TABLE 38 UAE Non Hodgkin Lymphoma Therapeutics Market by Therapy Type, 2023 - 2030, USD Million
TABLE 39 Saudi Arabia Non Hodgkin Lymphoma Therapeutics Market, 2019 - 2022, USD Million
TABLE 40 Saudi Arabia Non Hodgkin Lymphoma Therapeutics Market, 2023 - 2030, USD Million
TABLE 41 Saudi Arabia Non Hodgkin Lymphoma Therapeutics Market by Cell Type, 2019 - 2022, USD Million
TABLE 42 Saudi Arabia Non Hodgkin Lymphoma Therapeutics Market by Cell Type, 2023 - 2030, USD Million
TABLE 43 Saudi Arabia Non Hodgkin Lymphoma Therapeutics Market by Therapy Type, 2019 - 2022, USD Million
TABLE 44 Saudi Arabia Non Hodgkin Lymphoma Therapeutics Market by Therapy Type, 2023 - 2030, USD Million
TABLE 45 South Africa Non Hodgkin Lymphoma Therapeutics Market, 2019 - 2022, USD Million
TABLE 46 South Africa Non Hodgkin Lymphoma Therapeutics Market, 2023 - 2030, USD Million
TABLE 47 South Africa Non Hodgkin Lymphoma Therapeutics Market by Cell Type, 2019 - 2022, USD Million
TABLE 48 South Africa Non Hodgkin Lymphoma Therapeutics Market by Cell Type, 2023 - 2030, USD Million
TABLE 49 South Africa Non Hodgkin Lymphoma Therapeutics Market by Therapy Type, 2019 - 2022, USD Million
TABLE 50 South Africa Non Hodgkin Lymphoma Therapeutics Market by Therapy Type, 2023 - 2030, USD Million
TABLE 51 Nigeria Non Hodgkin Lymphoma Therapeutics Market, 2019 - 2022, USD Million
TABLE 52 Nigeria Non Hodgkin Lymphoma Therapeutics Market, 2023 - 2030, USD Million
TABLE 53 Nigeria Non Hodgkin Lymphoma Therapeutics Market by Cell Type, 2019 - 2022, USD Million
TABLE 54 Nigeria Non Hodgkin Lymphoma Therapeutics Market by Cell Type, 2023 - 2030, USD Million
TABLE 55 Nigeria Non Hodgkin Lymphoma Therapeutics Market by Therapy Type, 2019 - 2022, USD Million
TABLE 56 Nigeria Non Hodgkin Lymphoma Therapeutics Market by Therapy Type, 2023 - 2030, USD Million
TABLE 57 Rest of LAMEA Non Hodgkin Lymphoma Therapeutics Market, 2019 - 2022, USD Million
TABLE 58 Rest of LAMEA Non Hodgkin Lymphoma Therapeutics Market, 2023 - 2030, USD Million
TABLE 59 Rest of LAMEA Non Hodgkin Lymphoma Therapeutics Market by Cell Type, 2019 - 2022, USD Million
TABLE 60 Rest of LAMEA Non Hodgkin Lymphoma Therapeutics Market by Cell Type, 2023 - 2030, USD Million
TABLE 61 Rest of LAMEA Non Hodgkin Lymphoma Therapeutics Market by Therapy Type, 2019 - 2022, USD Million
TABLE 62 Rest of LAMEA Non Hodgkin Lymphoma Therapeutics Market by Therapy Type, 2023 - 2030, USD Million
TABLE 63 Key Information – Pfizer, Inc.
TABLE 64 Key Information – F. Hoffmann-La Roche Ltd.
TABLE 65 Key Information – Sanofi S.A.
TABLE 66 Key information – AbbVie, Inc.
TABLE 67 Key Information – Novartis AG
TABLE 68 Key Information – GlaxoSmithKline PLC
TABLE 69 Key Information – Johnson & Johnson
TABLE 70 Key Information – Takeda Pharmaceutical Company Limited
TABLE 71 Key Information – Bayer AG
TABLE 72 Key Information – Bristol-Myers Squibb Company
List of Figures
FIG 1 Methodology for the research
FIG 2 LAMEA Non Hodgkin Lymphoma Therapeutics Market, 2019 - 2030, USD Million
FIG 3 Key Factors Impacting Non Hodgkin Lymphoma Therapeutics Market
FIG 4 Porter’s Five Forces Analysis – Non Hodgkin Lymphoma Therapeutics Market
FIG 5 LAMEA Non Hodgkin Lymphoma Therapeutics Market share by Cell Type, 2022
FIG 6 LAMEA Non Hodgkin Lymphoma Therapeutics Market share by Cell Type, 2030
FIG 7 LAMEA Non Hodgkin Lymphoma Therapeutics Market by Cell Type, 2019 - 2030, USD Million
FIG 8 LAMEA Non Hodgkin Lymphoma Therapeutics Market share by Therapy Type, 2022
FIG 9 LAMEA Non Hodgkin Lymphoma Therapeutics Market share by Therapy Type, 2030
FIG 10 LAMEA Non Hodgkin Lymphoma Therapeutics Market by Therapy Type, 2019 - 2030, USD Million
FIG 11 LAMEA Non Hodgkin Lymphoma Therapeutics Market share by Country, 2022
FIG 12 LAMEA Non Hodgkin Lymphoma Therapeutics Market share by Country, 2030
FIG 13 LAMEA Non Hodgkin Lymphoma Therapeutics Market by Cell Type, 2019 - 2030, USD Million
FIG 14 Recent strategies and developments: Pfizer Inc.
FIG 15 SWOT Analysis: Pfizer, Inc.
FIG 16 Swot Analysis: F. Hoffmann-La Roche Ltd.
FIG 17 Swot Analysis: Sanofi S.A.
FIG 18 Swot Analysis: AbbVie, Inc.
FIG 19 SWOT Analysis: Novartis AG
FIG 20 SWOT Analysis: GlaxoSmithKline PLC
FIG 21 SWOT Analysis: Johnson & Johnson
FIG 22 SWOT Analysis:Takeda Pharmaceutical Company Limited
FIG 23 Swot Analysis: Bayer AG
FIG 24 SWOT Analysis: Bristol-Myers Squibb Company